Simcere Pharmaceutical Group.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Simcere Pharmaceutical Group. beat expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share contracted significantly.
Gross margins dropped, operating margins expanded, net margins shrank.
Simcere Pharmaceutical Group. logged revenue of $84.6 million. The two analysts polled by S&P Capital IQ hoped for revenue of $82.3 million on the same basis. GAAP reported sales were 6.7% higher than the prior-year quarter's $78.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.01. The two earnings estimates compiled by S&P Capital IQ averaged $0.07 per share. GAAP EPS of $0.07 for Q3 were 30% lower than the prior-year quarter's $0.10 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 83.6%, 100 basis points worse than the prior-year quarter. Operating margin was 6.2%, 270 basis points better than the prior-year quarter. Net margin was 4.2%, 260 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $86.9 million. On the bottom line, the average EPS estimate is $0.10.
Next year's average estimate for revenue is $333.6 million. The average EPS estimate is $0.32.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 223 members out of 233 rating the stock outperform, and 10 members rating it underperform. Among 39 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give Simcere Pharmaceutical Group. a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Simcere Pharmaceutical Group. is hold, with an average price target of $8.60.
- Add Simcere Pharmaceutical Group. to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.